Sivik Global Healthcare LLC bought a new position in shares of Centene Corporation (NYSE:CNC – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 80,000 shares of the company’s stock, valued at approximately $4,970,000. Centene makes up about 3.1% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 14th biggest position.
Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. acquired a new stake in Centene during the second quarter worth about $2,660,422,000. Wellington Management Group LLP raised its position in shares of Centene by 423.0% in the 2nd quarter. Wellington Management Group LLP now owns 13,301,215 shares of the company’s stock valued at $853,805,000 after buying an additional 10,757,914 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Centene by 12.4% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,517,580 shares of the company’s stock worth $354,173,000 after acquiring an additional 608,249 shares during the period. Bank of America Corp DE bought a new stake in shares of Centene during the 2nd quarter worth approximately $285,713,000. Finally, Deutsche Bank AG acquired a new stake in shares of Centene during the 2nd quarter worth approximately $257,279,000. Institutional investors and hedge funds own 93.63% of the company’s stock.
Centene Trading Up 3.7%
NYSE CNC traded up $2.46 on Tuesday, reaching $69.48. The company had a trading volume of 2,427,616 shares, compared to its average volume of 5,643,640. The firm has a market cap of $34.32 billion, a price-to-earnings ratio of -6.65, a P/E/G ratio of 0.41 and a beta of 1.13. Centene Corporation has a fifty-two week low of $31.63 and a fifty-two week high of $69.63. The business has a 50 day moving average of $65.05 and a two-hundred day moving average of $58.82. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.15 and a quick ratio of 1.15.
Analyst Ratings Changes
A number of research analysts recently issued reports on the stock. Morgan Stanley set a $66.00 price objective on shares of Centene in a research note on Wednesday, July 29th. Wall Street Zen upgraded Centene from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 18th. Stifel Nicolaus set a $79.00 target price on Centene in a report on Monday, August 3rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Centene in a research note on Friday. Finally, Argus raised Centene from a “hold” rating to a “buy” rating and set a $80.00 price target for the company in a report on Tuesday, August 11th. Nine investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $70.05.
Read Our Latest Report on Centene
Insider Activity at Centene
In related news, General Counsel Christopher Koster sold 56,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $66.90, for a total value of $3,779,850.00. Following the sale, the general counsel directly owned 248,854 shares in the company, valued at $16,648,332.60. This represents a 18.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.37% of the stock is currently owned by corporate insiders.
Centene Company Profile
Centene Corporation (NYSE:CNC) is a healthcare enterprise that provides health insurance and related services, primarily through government-sponsored programs. Its offerings include Medicaid plans, Medicare products, health plans sold through the Affordable Care Act marketplace, and services for military families through government-sponsored healthcare programs.
The company also provides pharmacy, behavioral health, specialty healthcare, care management and administrative services through various subsidiaries and partner organizations.
Further Reading
- Five stocks we like better than Centene
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
- IonQ Fell 9% on a $1.3 Billion Deal—Is Wall Street Missing Something?
Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.
